Labcorp Holdings Inc. $LH Stock Acquired by Willis Investment Counsel

Willis Investment Counsel boosted its position in Labcorp Holdings Inc. (NYSE:LH) by 6.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,041 shares of the medical research company’s stock after purchasing an additional 4,722 shares during the quarter. Willis Investment Counsel’s holdings in Labcorp were worth $24,661,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LH. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Labcorp by 2.8% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 10,661 shares of the medical research company’s stock worth $3,285,000 after purchasing an additional 287 shares during the period. CWA Asset Management Group LLC bought a new stake in shares of Labcorp during the 3rd quarter valued at $279,000. Richards Merrill & Peterson Inc. acquired a new stake in shares of Labcorp during the 3rd quarter worth $228,000. Weybosset Research & Management LLC grew its holdings in shares of Labcorp by 0.5% during the 3rd quarter. Weybosset Research & Management LLC now owns 39,653 shares of the medical research company’s stock worth $12,217,000 after purchasing an additional 214 shares in the last quarter. Finally, TD Waterhouse Canada Inc. increased its position in shares of Labcorp by 69.3% in the third quarter. TD Waterhouse Canada Inc. now owns 977 shares of the medical research company’s stock worth $297,000 after purchasing an additional 400 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Labcorp

In related news, CEO Adam H. Schechter sold 4,669 shares of Labcorp stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the sale, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kerrii B. Anderson sold 3,000 shares of Labcorp stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $318.02, for a total transaction of $954,060.00. Following the sale, the director directly owned 6,563 shares in the company, valued at $2,087,165.26. This trade represents a 31.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 8,593 shares of company stock valued at $2,733,295. 0.84% of the stock is currently owned by insiders.

Labcorp Price Performance

Shares of Labcorp stock traded up $3.74 during trading on Tuesday, reaching $322.57. 163,499 shares of the company’s stock were exchanged, compared to its average volume of 687,721. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. Labcorp Holdings Inc. has a 1-year low of $244.52 and a 1-year high of $341.80. The company has a market cap of $26.16 billion, a P/E ratio of 26.68, a PEG ratio of 1.81 and a beta of 0.87. The firm’s 50-day moving average price is $320.55 and its 200 day moving average price is $289.63.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping the consensus estimate of $4.78 by $0.21. The business had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. Labcorp’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, research analysts anticipate that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

LH has been the subject of a number of analyst reports. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. UBS Group increased their price objective on shares of Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Truist Financial raised their target price on shares of Labcorp from $350.00 to $365.00 and gave the company a “buy” rating in a report on Monday, September 21st. Piper Sandler boosted their target price on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $306.00 price target on shares of Labcorp in a report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $337.73.

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.